Squarepoint’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-28,005
| Closed | -$169K | – | 2835 |
|
|
2019
Q4 | $169K | Sell |
28,005
-244,460
| -90% | -$1.41M | ﹤0.01% | 2259 |
|
|
2019
Q3 | $981K | Buy |
272,465
+141,297
| +108% | +$545K | 0.01% | 1246 |
|
|
2019
Q2 | $352K | Buy |
131,168
+89,761
| +217% | +$265K | ﹤0.01% | 1854 |
|
|
2019
Q1 | $123K | Sell |
41,407
-10,921
| -21% | -$26.8K | ﹤0.01% | 2013 |
|
|
2018
Q4 | $83K | Sell |
52,328
-319,329
| -86% | -$903K | ﹤0.01% | 1815 |
|
|
2018
Q3 | $1.37M | Buy |
371,657
+148,972
| +67% | +$444K | 0.02% | 853 |
|
|
2018
Q2 | $630K | Buy |
+222,685
| New | +$758K | 0.01% | 1082 |
|
|
2018
Q1 | – | Sell |
-232,146
| Closed | -$669K | – | 2377 |
|
|
2017
Q4 | $669K | Buy |
232,146
+183,895
| +381% | +$668K | 0.01% | 1019 |
|
|
2017
Q3 | $217K | Buy |
+48,251
| New | +$214K | ﹤0.01% | 1347 |
|
|
2017
Q2 | – | Sell |
-58,268
| Closed | -$245K | – | 1946 |
|
|
2017
Q1 | $245K | Sell |
58,268
-94,557
| -62% | -$393K | 0.01% | 1191 |
|
|
2016
Q4 | $631K | Buy |
152,825
+117,825
| +337% | +$626K | 0.03% | 708 |
|
|
2016
Q3 | $284K | Sell |
35,000
-21,400
| -38% | -$182K | 0.02% | 753 |
|
|
2016
Q2 | $440K | Buy |
56,400
+27,300
| +94% | +$234K | 0.03% | 599 |
|
|
2016
Q1 | $225K | Sell |
29,100
-41,700
| -59% | -$305K | 0.02% | 957 |
|
|
2015
Q4 | $764K | Buy |
+70,800
| New | +$644K | 0.08% | 347 |
|
Squarepoint's ACHN Position: Q1 2020 in Review
Squarepoint sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 28,005 shares — an estimated $169K sold.
Squarepoint first reported a position in ACHN in Q4 2015 and held it in 15 quarters. The position peaked at $1.37M in Q3 2018. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Squarepoint reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Squarepoint sold 28,005 Achillion Pharmaceuticals shares in Q1 2020, an estimated $169K.
- Squarepoint first reported a position in Achillion Pharmaceuticals in Q4 2015 and held it in 15 quarters.
- Squarepoint's Achillion Pharmaceuticals position peaked at $1.37M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Squarepoint's 13F filing for Q1 2020, filed 15 May 2020.